Discussion with JT about a week ago...
It did really occur to me until I looked at Amarin's balance sheet again...but one of the primary reasons JT mentioned as a reason not to appeal SPA further was the potential cost of litigation. IMO FDA has bled Amarin of cash with the arbitrary and capricious Regulation of both Marine sNDA (No NCE) and rescindment of Anchor, to the point Amarin had to layoff sales reps after the ANCHOR rescindment. Both these issue revolve aroung ALL of Amarin's legal costs fighting NCE, Patents, Appeals of NCE, and SAC with New Jersey investors.
If sales don't grow, and RI is still enrolling..."now over 8,000"...I really question the solvency of Amarin's business plan. RI will not be approve in those next twelve months, & it's impossible to grow scrips without SOV (more reps/share of voice).
I want that appeal filed ASAP and Amarin isn't/can't afford to follow through.
BB
News 
Market Data 
Discover 
